Education
About Us
Working with TipRanks
Follow Us
ARS Pharmaceuticals (SPRY)
NASDAQ:SPRY
Total Valuation
ARS Pharmaceuticals has a market cap or net worth of $1.32B. The enterprise value is $1.32B.
Market Cap$1.32B
Enterprise Value$1.32B
Share Statistics
ARS Pharmaceuticals has 98,213,560 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding98,213,560
Owned by Insiders70.37%
Owned by Institutions0.02%
Financial Efficiency
ARS Pharmaceuticals’s return on equity (ROE) is 0.03 and return on invested capital (ROIC) is -0.91%.
Return on Equity (ROE)0.03
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)-0.91%
Return on Capital Employed (ROCE)>-0.01
Revenue Per Employee575.15K
Profits Per Employee51.60K
Employee Count155
Asset Turnover0.25
Inventory Turnover0.19
Valuation Ratios
The current PE Ratio of ARS Pharmaceuticals is 127.87. ARS Pharmaceuticals’s PEG ratio is 0.29.
PE Ratio127.87
PS Ratio0.00
PB Ratio5.92
Price to Fair Value3.98
Price to FCF-64.47
Price to Operating Cash Flow-66.16
PEG Ratio0.29
Income Statement
In the last 12 months, ARS Pharmaceuticals had revenue of 89.15M and earned 8.00M in profits. Earnings per share was 0.08.
Revenue89.15M
Gross Profit88.17M
Operating Income-3.08M
Pretax Income8.29M
Net Income8.00M
EBITDA-2.88M
Earnings Per Share (EPS)0.08
Cash Flow
In the last 12 months, operating cash flow was -20.48M and capital expenditures -571.00K, giving a free cash flow of -21.05M billion.
Operating Cash Flow-20.48M
Free Cash Flow-21.05M
Free Cash Flow per Share-0.21
Dividends & Yields
ARS Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.60
52-Week Price Change64.47%
50-Day Moving Average13.86
200-Day Moving Average13.29
Relative Strength Index (RSI)53.46
Average Volume (3m)1.32M
Important Dates
ARS Pharmaceuticals upcoming earnings date is Aug 6, 2025, TBA Not Confirmed.
Last Earnings DateMay 14, 2025
Next Earnings DateAug 6, 2025
Ex-Dividend Date―
Financial Position
ARS Pharmaceuticals as a current ratio of 14.26, with Debt / Equity ratio of 0.03%
Current Ratio14.26
Quick Ratio14.04
Debt to Market Cap<0.01
Net Debt to EBITDA16.47
Interest Coverage Ratio0.00
Taxes
In the past 12 months, ARS Pharmaceuticals has paid 288.00K in taxes.
Income Tax288.00K
Effective Tax Rate0.03
Enterprise Valuation
ARS Pharmaceuticals EV to EBITDA ratio is -315.25, with an EV/FCF ratio of 74.85.
EV to Sales10.90
EV to EBITDA-315.25
EV to Free Cash Flow74.85
EV to Operating Cash Flow71.74
Balance Sheet
ARS Pharmaceuticals has $275.73M in cash and marketable securities with $73.00K in debt, giving a net cash position of -$275.65M billion.
Cash & Marketable Securities$275.73M
Total Debt$73.00K
Net Cash-$275.65M
Net Cash Per Share-$2.81
Tangible Book Value Per Share$2.57
Margins
Gross margin is 90.74%, with operating margin of -3.46%, and net profit margin of 8.97%.
Gross Margin90.74%
Operating Margin-3.46%
Pretax Margin9.29%
Net Profit Margin8.97%
EBITDA Margin-3.46%
EBIT Margin-3.46%
Analyst Forecast
The average price target for ARS Pharmaceuticals is $29.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$29.50
Price Target Upside119.49% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast971120.00%
EPS Growth Forecast68.69%